We are a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Meet the team »
We are currently enrolling the Phase 2 portion of an accelerated Phase 2/3 study of RPC1063 in RMS. More information about RADIANCE enrolling locations and patient eligibility requirements can be found here.
We are currently enrolling the Phase 2 study of RCP1063 in Ulcerative Colitis. More information about TOUCHSTONE enrolling locations and patient eligibility requirements can be found here.
June 5, 2013
Receptos Provides Update on Progress of Lead Product Candidate RPC1063… MORE »
May 29, 2013
Receptos to Present at Jefferies 2013 Global Healthcare Conference… MORE »
May 15, 2013
Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease… MORE »
May 14, 2013
Receptos Announces Completion of Initial Public Offering of Common Stock… MORE »